ATNF (180 Life Sciences) Beneish M-Score : 0.00 (As of Mar. 14, 2025)

View and export this data going back to 2017. Start your Free Trial

What is 180 Life Sciences Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for 180 Life Sciences's Beneish M-Score or its related term are showing as below:

During the past 5 years, the highest Beneish M-Score of 180 Life Sciences was 0.00. The lowest was 0.00. And the median was 0.00.

180 Life Sciences Beneish M-Score Historical Data

The historical data trend for 180 Life Sciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

180 Life Sciences Beneish M-Score Chart

180 Life Sciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Beneish M-Score

180 Life Sciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Beneish M-Score	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of 180 Life Sciences's Beneish M-Score

For the Biotechnology subindustry, 180 Life Sciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

180 Life Sciences's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 180 Life Sciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where 180 Life Sciences's Beneish M-Score falls into.

180 Life Sciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of 180 Life Sciences for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Sep24) TTM:

Last Year (Sep23) TTM:

Total Receivables was $0.04 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $1.23 Mil.
Total Assets was $10.47 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.09 Mil.
Selling, General, & Admin. Expense(SGA) was $4.85 Mil.
Total Current Liabilities was $6.38 Mil.
Long-Term Debt & Capital Lease Obligation was $0.01 Mil.
Net Income was -0.837 + 0.012 + -1.07 + -1.227 = $-3.12 Mil.
Non Operating Income was 0.156 + 1.87 + 1.039 + 0.231 = $3.30 Mil.
Cash Flow from Operations was -0.224 + 0.727 + -1.033 + -2.16 = $-2.69 Mil.

Total Receivables was $0.13 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $3.37 Mil.
Total Assets was $4.96 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.12 Mil.
Selling, General, & Admin. Expense(SGA) was $14.26 Mil.
Total Current Liabilities was $4.81 Mil.
Long-Term Debt & Capital Lease Obligation was $0.02 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(0.044 / 0)	/	(0.13 / 0)
	=		/
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0 / 0)	/	(0 / 0)
	=		/
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (1.225 + 0) / 10.47)	/	(1 - (3.371 + 0) / 4.958)
	=	0.882999	/	0.320089
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0	/	0
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.122 / (0.122 + 0))	/	(0.085 / (0.085 + 0))
	=	1	/	1
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(4.847 / 0)	/	(14.258 / 0)
	=		/
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0.011 + 6.384) / 10.47)	/	((0.022 + 4.807) / 4.958)
	=	0.610793	/	0.973981
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-3.122 - 3.296	-	-2.69)	/	10.47
	=	-0.356065

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

180 Life Sciences Beneish M-Score Related Terms

Thank you for viewing the detailed overview of 180 Life Sciences's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

180 Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 180 Life Sciences Corp (NAS:ATNF) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA, USA, 94306

Website

https://www.180lifesciences.com

180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.

Executives

James N. Woody	director, officer: Chief Executive Officer	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Marc Feldmann	director	5 DURHAM TERRACE, LONDON X0 W25PB
Lawrence Steinman	director	10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Mcgovern Jr. Donald A.	director	C/O CARS.COM, 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Quan Anh Vu	officer: COO / Chief Business Officer	22616 ERWIN STREET, WOODLAND HILLS CA 91367
Ozan Pamir	officer: Interim CFO	2443 FILLMORE ST #380-17649, SAN FRANCISCO CA 94115
Pamela G Marrone	director	C/O MARRONE BIO INNOVATIONS, INC., 2121 SECOND STREET, A-107, DAVIS CA 95618
Teresa Deluca	director	40 BURTON HILLS BOULEVARD, SUITE 500, NASHVILLE TN 37215
Russell T Ray	director	2525 DUPONT DR, IRVINE CA 92612
Knuettel Ii Francis	director	205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701
Marlene Krauss	director, 10 percent owner, officer: Chief Executive Officer	C/O KBL HEALTHCARE INC, 645 MADISON AVE, NEW YORK NY 10022
Lawrence Marshall Gold	director	830 MENLO AVENUE, SUITE 100, MENLO PARK CA 94025
Jonathan B. Rothbard	officer: Chief Scientific Officer	501 BEALE STREET, UNIT 8D, SAN FRANCISCO CA 94105
Shoshana Shendelman	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Richard W Barker	director	290 COMMONWEALTH AVENUE #17, BOSTON MA 02115